Scope and Claims Analysis of US Patent 8,419,307 (Testosterone Axillary Liquid Delivery) and the US Patent Landscape
US Patent 8,419,307 is a US-method patent that claims a testosterone liquid administered by an applicator that spreads liquid over skin using a flexible, deformable membrane wall integrated with a base. The claim scope covers (i) the axillary route for raising serum testosterone, (ii) a specific applicator structure with a reservoir and a “working surface” formed by a resilient wall, and (iii) specific formulation ranges for testosterone solutions including high-voltage volatile solvent systems, lower alkyl alcohols, defined penetration enhancers, and viscosity modifiers.
The practical consequence is that the enforceable “claim hook” is not only testosterone-at-the-axilla, but the combination of testosterone formulation and a particular metering/spreading applicator geometry. Competitors that can avoid either (a) the applicator structure limitations or (b) the claimed formulation parameterization have multiple design-around paths, even if they share the same general route.
What does US 8,419,307 claim for axillary testosterone delivery using a membrane reservoir applicator?
What is the core independent claim (Claim 1) covering
Claim 1 is directed to:
- Therapeutic method: increasing testosterone blood level in a person in need thereof
- Route/location: apply to at least one axilla
- Dosage form: a liquid pharmaceutical composition comprising testosterone and a carrier
- Delivery implement (structural limitations):
- a support
- a receptacle mounted on the support defining a reservoir space with an open top
- liquid is received via the open top into the reservoir
- receptacle includes a flexible membrane integrally forming:
- a base
- a wall substantially transverse to the base
- the wall has a working surface configured to spread liquid over the treatment surface
- the base has a continuous surface so liquid cannot pass through the base
- the wall has:
- an inner portion extending from base to upper end
- an outer skirt portion
- inner portion + outer skirt form a double-wall structure
- at least the wall is resiliently deformable so that in use the working surface maintains contact with the skin while spreading liquid
What the claim requires to “land”
To infringe Claim 1, an accused method must generally satisfy all of the following at once:
- Testosterone is delivered to at least one axilla.
- Delivery uses a liquid formulation.
- Administration uses an applicator that matches the described reservoir + flexible membrane base/wall + double-wall + non-permeable base + resilient working surface contact feature set.
- The membrane wall is used specifically to spread the liquid on the treatment surface.
If any of the structural applicator limitations are not met, the method may not fall within Claim 1 even if the user applies testosterone under the arm.
How broad is the claim scope compared with typical transdermal or topical testosterone patents?
Claim 1 is narrower than “axillary testosterone composition” patents
Many testosterone topical patents focus on composition and/or route (e.g., gel, lotion, patch) without binding the delivery device structure. US 8,419,307 binds to a device-defined spreading mechanism, which narrows infringement exposure for any competitor using a different device class (pump-and-apply dropper, aerosols, wands without a deformable double-wall membrane, patches, or roll-on heads that do not use the membrane geometry described).
The “base continuous surface” limitation is a strong device discriminator
The base is explicitly described as a continuous surface such that liquid cannot pass through. That limitation is functionally a barrier requirement that can help distinguish from porous or permeable bases.
The “double-wall” membrane geometry is a key claim feature
The inner portion + outer skirt portion form a “double-wall structure.” Rollers and wicks can spread liquid, but may not have the same integrated double-wall membrane structure.
Which dependent claims define formulation scope (alcohols, penetration enhancers, viscosity modifiers, and ranges)?
What Claim 2 adds: formulation boundaries
Claim 2 depends from Claim 1 and limits the liquid composition to include:
- Testosterone in a pharmaceutically effective amount
- Lower alkyl alcohol(s): combined amount at least 60% v/v
- Penetration enhancer(s)
- Viscosity modulating agent to increase viscosity
This claim is a composition-specific narrowing of Claim 1. A product with the correct applicator but different solvent system may fall outside Claim 2.
Which penetration enhancers are enumerated (Claim 3)
Claim 3 recites a long list of acceptable penetration enhancers including:
- Fatty acids / esters / alcohols
- Glycols / glycol esters
- 1,3-dioxolanes / 1,3-dioxanes
- Macrocyclic ketones with at least 12 carbons
- Oxazolidinones and oxazolidinone derivatives
- Alkyl-2-(N,N-disubstituted amino)-alkanoate esters
- (N,N-disubstituted amino)-alkanol alkanoates
- Sunscreen esters
- Mixtures
This is broad within the enumerated categories, but still limited to compounds of that list.
Claim 4 narrows further to a named subset
Claim 4 narrows enhancers to specific exemplars including:
- Glycols
- Oleic acid
- Isopropyl myristate
- Cyclopentadecanone
- Sorbitan monooleate
- Octisalate
- Octyldimethyl-para-aminobenzoate
- Octyl para-methoxycinnamate
- combinations
Claim 5 and 6: dosage form and viscosity envelope
- Claim 5: liquid is a lotion or gel
- Claim 6: viscosity > water and < 300 cP
This is an intermediate-level narrowing. Many topical liquids likely meet “> water,” but avoiding <300 cP is a possible design-around if viscosity can be controlled in formulation and still be deliverable with the device.
How does the patent scope change when the claims specify serum testosterone targets and male hypogonadism (Claims 7, 14–16)?
Claim 7
- Person is male with hypogonadism
- Serum testosterone level target: 300 to 1000 ng/dL
These target ranges are typical of clinically relevant testosterone levels, but the enforceability depends on proof that administration results in that range (or, depending on jurisdiction and claim construction, that the method is performed to achieve that range).
Claims 14–16
- Claim 13 depends into a more specific formulation (octyl salicylate, volatile solvent ethanol/isopropanol range, PVP viscosity modifier), then:
- Claim 14: male
- Claim 15: male hypogonadism
- Claim 16: serum target 300 to 1000 ng/dL
This makes serum targets doubly embedded: first as a clinical parameter in the method and second as a marker of an implied “successful” application of the claimed formulation and device.
What is the “device + formulation” relationship in Claim 13, and why does it matter?
Claim 13 is the most concrete combined embodiment
Claim 13 adds:
- All Claim 1 device limitations
- Plus a specific composition package:
- testosterone at effective amount
- octyl salicylate as penetration enhancer in 0.01% to 15% w/v
- volatile solvent selected from ethanol, isopropanol, or mixtures at total 70% to 99% v/v
- viscosity modulating agent to produce viscosity > water and < 300 cP
This claim compresses the space of both device and formulation to a commercially actionable recipe: ethanol/isopropanol-dominant volatile solvent plus octyl salicylate plus a viscosity modifier, delivered through the specified flexible membrane spreading applicator to the axilla.
Why Claim 13 is a litigation focal point
- It reduces argument space: less dependent claim variability.
- It ties a named penetration enhancer (octyl salicylate) to a tight solvent range and a viscosity window.
- If a challenger sells an axillary testosterone liquid using ethanol/isopropanol plus octyl salicylate with an appropriate spreading device, the probability of fitting Claim 13 is higher than under broader claims.
Which additional dependent claims specify packaging, pump connection, and reservoir handling (Claims 9–12, 17–18, 23)?
Pump/dispenser detachability
- Claim 9: support detachably connectable to a container with a pump dispenser delivering liquid to the receptacle
- Claim 10: support surrounds the pump to reduce inadvertent discharge
- Claim 17: Claim 9 structure applied in the Claim 13 context
- Claim 18: Claim 10 structure applied in the Claim 13 context
These are device-adjacent limitations. Many market deliverers use pump bottles; the “surrounds the pump” feature can differentiate.
Method steps for filling and deforming
- Claim 12: method includes applying liquid volume to the reservoir space and deforming the wall against the skin while spreading
- Claim 23: repeats the reservoir fill and wall deformation concept in the Claim 13 context
These add process steps that can matter for infringement where product design differs in operation sequence.
What formulation limitations are specified in Claims 19–22 (PVP, concentration, and testosterone levels)?
Viscosity modulator identification
- Claim 19: viscosity modulating agent is polyvinyl pyrrolidone (PVP)
- Claim 20: PVP in 1% to 3% w/v
Testosterone concentration
- Claim 21: testosterone at least 1% w/v
Volatile solvent minimum
- Claim 22: volatile solvent at least 80% v/v
These “composition recipe” claims can materially narrow infringement. Even if a competitor uses an ethanol-dominant system and octyl salicylate, deviation in PVP identity or concentration can avoid these dependent claims. Independent Claim 1 could still be implicated if the applicator structure matches and the competitor delivers testosterone to axilla using a liquid carrier, but Claim 1 does not recite the specific solvent/PVP/enhancer parameters.
US patent estate mapping approach for US 8,419,307 (what should be checked in Orange Book and litigation practice)
The user provided the claim text, but not bibliographic data for US 8,419,307 (assignee, priority date, expiration, prosecution history) and no product identifier (reference listed drug, NDC, or Orange Book listing). Without those facts, a complete landscape cannot be produced.
Accordingly, only claim-scope and design-around analytics grounded on the text provided are covered here. A full US litigation and Orange Book mapping would require patent numbers, assignees, and related family member identifiers.
Design-around opportunities based on claim construction (actionable for R&D and licensing diligence)
Avoid the membrane reservoir spreading architecture
To reduce or eliminate coverage under Claim 1/Claim 13, consider delivery approaches that do not include:
- a reservoir space with open top feeding into a receptacle
- an integrated flexible membrane base and wall
- double-wall inner portion + outer skirt portion
- resilient deformability maintaining working surface contact
- a continuous base preventing liquid passage
Practical device alternatives:
- fixed hard applicators without resilient membrane working surface
- controlled spray systems that do not rely on a deformable membrane spreading head
- patches or semi-solid formulations applied through non-membrane devices
Stay outside the specified formulation parameter stack for dependent claims
For Claim 2 and Claim 13 and their dependent narrowings:
- ensure the solvent system is not at least 60% v/v lower alkyl alcohols (Claim 2) or not 70–99% v/v ethanol/isopropanol (Claim 13)
- replace octyl salicylate with a non-listed enhancer (if aiming to avoid Claim 3/4/13) or use an enhancer outside the enumerated list
- adjust penetration enhancer concentration outside 0.01% to 15% w/v (Claim 13)
- adjust viscosity outside > water and <300 cP (Claims 6, 13)
- replace PVP as viscosity modulator or adjust PVP outside 1–3% w/v (Claims 19–20)
- adjust testosterone concentration below 1% w/v (Claim 21)
- use volatile solvent below 80% v/v (Claim 22)
Operational method deviations
Claim 12/23 add method steps around applying to reservoir space and deforming wall against skin. A process that uses a different dispensing mechanism (no reservoir fill and no wall deformation step) can shift infringement risk away from these dependent claims.
Key takeaways
- US 8,419,307’s enforcement focus is the combination of axillary testosterone liquid delivery with a specific flexible membrane applicator (reservoir, non-permeable base, resilient deformable double-wall membrane working surface).
- Dependent claims add substantial formulation specificity, especially ethanol/isopropanol 70–99% v/v and octyl salicylate 0.01–15% w/v (Claim 13), plus PVP 1–3% w/v, viscosity <300 cP, and testosterone ≥1% w/v.
- Design-around is most feasible by changing either the applicator device architecture (best for Claim 1/13 avoidance) or the formulation parameterization (best for Claim 2/13 dependent avoidance).
FAQs
-
What device features are most important to avoid infringement of US 8,419,307 Claim 1?
The integrated flexible membrane base and wall, the non-permeable continuous base, the double-wall inner/outer skirt structure, and resilient deformability maintaining skin contact for spreading.
-
Does the patent cover axillary testosterone using any testosterone gel or lotion?
Not broadly. Claim 1 requires the specific membrane-based applicator structure; dependent claims require specific formulation and viscosity constraints.
-
Is octyl salicylate required for all claims in US 8,419,307?
No. Octyl salicylate is explicitly required for Claim 13, but Claim 1 can be implicated without that specific enhancer if other limitations are met.
-
Can changing PVP concentration avoid the narrower claims?
Yes for PVP-dependent claims (Claims 19–20). Adjusting viscosity modulator identity or concentration can avoid those dependent limitations.
-
Does the patent require demonstration of serum testosterone achieving 300–1000 ng/dL?
Claims 7 and 16 include that serum range as a method outcome/goal. Whether that becomes a proving requirement depends on claim interpretation and litigation posture, but the range is explicitly recited.
References
No references are provided because the prompt includes only claim text and does not include bibliographic metadata or any cited sources to support an Orange Book, expiration, or litigation landscape.
